Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

Ramesh K. Ramanathan, Shannon L. McDonough, Hagen F. Kennecke, Syma Iqbal, Joaquina C. Baranda, Tara E. Seery, Howard J. Lim, Aram F. Hezel, Gina M. Vaccaro, Charles D. Blanke

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)'. Together they form a unique fingerprint.

Medicine & Life Sciences